Amendments to the Claims:

The following listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) An injectable pharmaceutical composition containing 8 to 16 mg/mL of glycyrrhizin, 3 to 6 mg/mL of cysteine and 80 to 160 mg/mL of aminoacetic ~~acid~~ acid,

wherein substantially no sulfite is contained in the pharmaceutical composition, and

wherein the glycyrrhizin, cysteine and aminoacetic acid are dissolved in water.

2. (Canceled)

3. (Previously Presented) The injectable pharmaceutical composition according to claim 1, wherein glycyrrhizin is monoammonium glycyrrhizinate.

4. (Previously Presented) The injectable pharmaceutical composition according to claim 1, wherein cysteine is cysteine hydrochloride.

5-8. (Canceled)

9. (Previously Presented) The injectable pharmaceutical composition according to claim 1, wherein the concentration of cysteine in the pharmaceutical composition after the composition is stored at 60°C for 14 days is more than 70% of an initial concentration of cysteine in the pharmaceutical composition.

10. (Currently Amended) An injectable pharmaceutical composition containing 8 to 16 mg/mL (as glycyrrhizin) of monoammonium glycyrrhizinate, 4 to 8 mg/mL of cysteine hydrochloride and 80 to 160 mg/mL of aminoacetic acid,

wherein substantially no sulfite is contained in the pharmaceutical composition, and

wherein the monoammonium glycyrrhizinate, cysteine and aminoacetic acid are dissolved in water.

11. (Withdrawn-Currently Amended) A method of treating hepatic diseases comprising: administering intravenously to a patient an injectable pharmaceutical composition containing 8 to 16 mg/mL of glycyrrhizin, 3 to 6 mg/mL of cysteine and 80 to 160 mg/mL of aminoacetic acid,

wherein substantially no sulfite is contained in the pharmaceutical composition, and

wherein the glycyrrhizin, cysteine and aminoacetic acid are dissolved in water.

12. (Withdrawn-Currently Amended) A method of treating allergy comprising: administering intravenously to a patient an injectable pharmaceutical composition containing 8 to 16 mg/mL of glycyrrhizin, 3 to 6 mg/mL of cysteine and 80 to 160 mg/mL of aminoacetic acid,

wherein substantially no sulfite is contained in the pharmaceutical composition, and

wherein the glycyrrhizin, cysteine and aminoacetic acid are dissolved in water.

13. (Withdrawn-Currently Amended) A method of treating hepatic diseases comprising: administering intravenously to a patient an injectable pharmaceutical composition containing 8 to 16 mg/mL (as glycyrrhizin) of monoammonium glycyrrhizinate, 4 to 8 mg/mL of cysteine hydrochloride and 80 to 160 mg/mL of aminoacetic acid,

wherein substantially no sulfite is contained in the pharmaceutical composition, and

wherein the glycyrrhizin, cysteine and aminoacetic acid are dissolved in water.

14. (Withdrawn-Currently Amended) A method of treating allergy comprising: administering intravenously to a patient an injectable pharmaceutical composition containing 8 to 16 mg/mL (as glycyrrhizin) of monoammonium glycyrrhizinate, 4 to 8 mg/mL of cysteine hydrochloride and 80 to 160 mg/mL of aminoacetic acid,

wherein substantially no sulfite is contained in the pharmaceutical composition, and

wherein the glycyrrhizin, cysteine and aminoacetic acid are dissolved in water.